Apple Inc. v. Vidal

63 F.4th 1
CourtCourt of Appeals for the Federal Circuit
DecidedMarch 13, 2023
Docket22-1249
StatusPublished
Cited by13 cases

This text of 63 F.4th 1 (Apple Inc. v. Vidal) is published on Counsel Stack Legal Research, covering Court of Appeals for the Federal Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Apple Inc. v. Vidal, 63 F.4th 1 (Fed. Cir. 2023).

Opinion

Case: 22-1249 Document: 71 Page: 1 Filed: 03/13/2023

United States Court of Appeals for the Federal Circuit ______________________

APPLE INC., CISCO SYSTEMS, INC., GOOGLE LLC, INTEL CORPORATION, EDWARDS LIFESCIENCES CORPORATION, EDWARDS LIFESCIENCES LLC, Plaintiffs-Appellants

v.

KATHERINE K. VIDAL, UNDER SECRETARY OF COMMERCE FOR INTELLECTUAL PROPERTY AND DIRECTOR OF THE UNITED STATES PATENT AND TRADEMARK OFFICE, Defendant-Appellee ______________________

2022-1249 ______________________

Appeal from the United States District Court for the Northern District of California in No. 5:20-cv-06128-EJD, Judge Edward J. Davila. ______________________

Decided: March 13, 2023 ______________________

CATHERINE CARROLL, Wilmer Cutler Pickering Hale and Dorr LLP, Washington, DC, argued for all plaintiffs-appel- lants. Plaintiffs-appellants Apple Inc., Cisco Systems, Inc., Intel Corporation also represented by DAVID LEHN; REBECCA M. LEE, San Francisco, CA; MARK D. SELWYN, Palo Alto, CA; ALYSON ZUREICK, New York, NY. Case: 22-1249 Document: 71 Page: 2 Filed: 03/13/2023

NATHAN K. KELLEY, Perkins Coie LLP, Washington, DC, for plaintiff-appellant Google LLC. Also represented by ANDREW DUFRESNE, Madison, WI.

CHRISTY G. LEA, Knobbe, Martens, Olson & Bear, LLP, Irvine, CA, for plaintiffs-appellants Edwards Lifesciences Corporation, Edwards Lifesciences LLC. Also represented by JOHN B. SGANGA, JR.

WEILI J. SHAW, Appellate Staff, Civil Division, United States Department of Justice, Washington, DC, argued for defendant-appellee. Also represented by MICHAEL GRANSTON, DANIEL TENNY; MICHAEL S. FORMAN, THOMAS W. KRAUSE, AMY J. NELSON, FARHEENA YASMEEN RASHEED, Office of the Solicitor, United States Patent and Trade- mark Office, Alexandria, VA.

MARK S. DAVIES, Orrick, Herrington & Sutcliffe LLP, Washington, DC, for amici curiae Acushnet Company, Al- liance for Automotive Innovation, Comcast Cable Commu- nications, LLC, Computer and Communication Industry Association, Dell, Inc., Garmin International, Inc., Juniper Networks, Inc., Micron Technology Inc., SAS Institute, Inc., Symmetry, LLC, Taiwan Semiconductor Manufactur- ing Company, Ltd., Verizon Services Corp., VIZIO, Inc., VMware, Inc. Also represented by ALEXANDRA BURSAK, New York, NY.

JAMES OLIVA, American Honda Motor Co., Inc., Tor- rance, CA, for amicus curiae American Honda Motor Co., Inc.

ROBERT THOMAS SMITH, Katten Muchin Rosenman LLP, Washington, DC, for amicus curiae Mylan Pharma- ceuticals Inc. Also represented by ERIC THOMAS WERLINGER; DEEPRO MUKERJEE, LANCE SODERSTROM, New York, NY. Case: 22-1249 Document: 71 Page: 3 Filed: 03/13/2023

APPLE INC. v. VIDAL 3

MICHAEL BERTA, Arnold & Porter Kaye Scholer LLP, San Francisco, CA, for amicus curiae Tesla, Inc. Also rep- resented by JAMES SHERWOOD, Tesla, Inc., Washington, DC. ______________________

Before LOURIE, TARANTO, and STOLL, Circuit Judges. TARANTO, Circuit Judge. Plaintiffs are Apple Inc. and four other companies that have repeatedly been sued for patent infringement and thereafter petitioned the Director of the Patent and Trademark Office (PTO) to institute inter partes reviews (IPRs), under 35 U.S.C. §§ 311–319, so that the PTO’s Patent Trial and Appeal Board could adjudicate the petitions’ unpatentability challenges to patent claims that had been asserted against them in court. In the present action, brought against the Director in district court under the Administrative Procedure Act (APA), 5 U.S.C. §§ 701– 706, plaintiffs challenge instructions the Director issued to the Board to inform it how to exercise, under delegation by the Director, the Director’s discretion whether to institute a requested IPR. Plaintiffs assert that the instructions are likely to produce too many denials of institution requests. The district court dismissed the APA action on the ground that the Director’s instructions were made unreviewable by the IPR provisions of the patent statute. We affirm in part and reverse in part. We affirm the unreviewability dismissal of plaintiffs’ challenges to the instructions as being contrary to statute and arbitrary and capricious. No constitutional challenges are presented. But we reverse the unreviewability dismissal of plaintiffs’ challenge to the instructions as having been improperly issued because they had to be, but were not, promulgated through notice-and-comment rulemaking under 5 U.S.C. § 553. That challenge, we also hold, at least Apple had standing to present. We remand for further proceedings on Case: 22-1249 Document: 71 Page: 4 Filed: 03/13/2023

the lone surviving challenge. Like the district court, we do not reach the merits of that challenge. I A In the America Invents Act (AIA), Pub. L. No. 112-29, 125 Stat. 284 (2011), Congress authorized the filing of a petition asking the PTO to conduct an IPR of whether iden- tified claims in an issued patent comply with certain pa- tentability requirements of novelty or obviousness over prior art. 35 U.S.C. § 311(a)–(b). The Board is the PTO component assigned to perform the IPR adjudication if a review is instituted, id. §§ 6(b)(4), 316–318, with the Board’s “final written decision” in the IPR subject to appeal to this court, id. § 319; see id. § 141. But it is the PTO’s Director to whom Congress assigned the task of determin- ing whether to institute a review in the first place. Id. § 314(b); see Thryv, Inc. v. Click-To-Call Technologies, LP, 140 S. Ct. 1367, 1370–71 (2020). For the Director to institute, certain preconditions must be met. One prerequisite, for all petitions, is the crossing of a merits “threshold”: “The Director may not au- thorize an [IPR] to be instituted unless the Director deter- mines that the information presented in the petition . . . and any response . . . shows that there is a reasonable like- lihood that the petitioner would prevail with respect to at least 1 of the claims challenged in the petition.” 35 U.S.C. § 314(a). Another prerequisite, applicable in the predicta- bly common situation where the patent owner has already sued the petitioner (or a real party in interest or privy) for infringement of the patent, is compliance with a timing limit: The petition must be filed within one year after ser- vice of the infringement complaint. Id. § 315(b). Even when such requirements are met, however, the statute uses no language commanding institution. “The Director is permitted, but never compelled, to institute an IPR[, a]nd no petitioner has a right to such institution.” Case: 22-1249 Document: 71 Page: 5 Filed: 03/13/2023

APPLE INC. v. VIDAL 5

Mylan Laboratories Ltd. v. Janssen Pharmaceutica, N.V., 989 F.3d 1375, 1382 (Fed. Cir. 2021). The Supreme Court explained in SAS Institute, Inc. v. Iancu: “§ 314(a) invests the Director with discretion on the question whether to in- stitute review.” 138 S. Ct. 1348, 1356 (2018); see also Cuozzo Speed Technologies, LLC v. Lee, 579 U.S. 261, 273 (2016) (citing § 314(a) and stating: “no mandate to institute review”). Congress not only left the discretion to the Director but also protected its exercise from judicial review, even re- garding the mandatory threshold conditions for institution, at least where, as here, the court challenge is not on a con- stitutional ground. See Cuozzo, 579 U.S.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

In Re TESLA, INC.
Federal Circuit, 2026
In Re KAHOOT! As
Federal Circuit, 2026
In Re INTEL CORPORATION
Federal Circuit, 2026
Apple Inc. v. Squires
Federal Circuit, 2026
In Re HIGHLEVEL, INC.
Federal Circuit, 2025
Onyewuchi v. DOJ
Federal Circuit, 2025
US Inventor, Inc. v. PTO
Federal Circuit, 2025
Igt v. Zynga Inc.
Federal Circuit, 2025
Realtek Semiconductor Corporation v. Itc
131 F.4th 1309 (Federal Circuit, 2025)
Apple Inc. v. Iancu
N.D. California, 2024
Alliance Hippocratic Medicine v. FDA
78 F.4th 210 (Fifth Circuit, 2023)

Cite This Page — Counsel Stack

Bluebook (online)
63 F.4th 1, Counsel Stack Legal Research, https://law.counselstack.com/opinion/apple-inc-v-vidal-cafc-2023.